natgillin/translations-raw huggingface dataset:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alunbrig have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Alunbrig upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
It will also provide an alert card for patients summarising key safety information about the risk of lung disease with the medicine and what to do in case of signs and symptoms. 
Prav tako bo bolnikom zagotovila opozorilno kartico, v kateri bodo povzete ključne varnostne informacije o tveganju med zdravljenjem s tem zdravilom za bolezni pljuč ter kaj storiti v primeru znakov in simptomov teh neželenih učinkov.
Alunbrig was not compared with any other treatment or placebo (a dummy treatment). 
Zdravila Alunbrig niso primerjali z nobenim drugim zdravilom ali placebom (zdravilom brez zdravilne učinkovine).
For more information about using Alunbrig, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Alunbrig glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What is Alunbrig and what is it used for? 
Kaj je zdravilo Alunbrig in za kaj se uporablja?
What benefits of Alunbrig have been shown in studies? 
Kakšne koristi je zdravilo Alunbrig izkazalo v študijah?
Alunbrig can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines. 
Predpisovanje in izdaja zdravila Alunbrig je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
The most common serious side effects (which may affect more than 1 in 50 people) are pneumonitis (inflammation in the lungs), pneumonia (infection of the lungs) and dyspnoea. 
Najpogostejši resni neželeni učinki zdravila Alunbrig (ki lahko prizadenejo več kot 1 osebo od 50) so pneumonitis (vnetje pljuč), pljučnica in dispneja.
What are the risks associated with Alunbrig? 
Kakšna tveganja so povezana z zdravilom Alunbrig?
The patient's cancer should be tested before starting treatment to confirm it has the gene changes affecting ALK (‘ALK-positive' status). 
Rak bolnika je treba pred začetkom zdravljenja pregledati, da bi potrdili prisotnost genske spremembe, ki vpliva na anaplastično limformsko kinazo (da je rak ALK-poizitiven).
Alunbrig has been shown to be effective in treating ALK-positive NSCLC in one main study involving 222 patients in whom the disease progressed despite previous treatment with crizotinib. 
Zdravilo Alunbrig se je izkazalo za učinkovito pri zdravljenju ALK-pozitivnega nedrobnoceličnega pljučnega raka v eni glavni študiji, ki je vključevala 222 bolnikov, katerih bolezen je napredovala kljub predhodnemu zdravljenju z krizotinibom.
The company that markets Alunbrig will submit the results of an ongoing study on the effectiveness and safety of Alunbrig in patients with ALK-positive NSCLC who have not received previous treatment targeted to ALK. 
Družba, ki trži zdravilo Alunbrig, bo predložila rezultate tekoče študije o učinkovitosti in varnosti zdravila pri bolnikih z ALK-pozitivnim nedrobnoceličnim rakom pljuč, ki niso bili predhodno zdravljeni s ciljnimi zdravili za ALK.
The active substance in Alunbrig, brigatinib, works by blocking the activity of ALK, thereby reducing the growth and spread of the cancer. 
Učinkovina v zdravilu Alunbrig, brigatinib, deluje tako, da zavira aktivnost anaplastične limfomske kinaze, s čimer zmanjšuje rast in širjenje raka.
ALK belongs to a family of enzymes called receptor tyrosine kinases (RTKs), which are involved in the growth of cells and the development of new blood vessels that supply them. 
Anaplastična limfomska kinaza spada v skupino encimov, imenovanih receptorji tirozin-kinaze (RTK), ki sodelujejo pri rasti celic in razvoju novih krvnih žil, ki te celice oskrbujejo.
Reduced doses are recommended in patients with severely reduced liver or kidney function. 
Pri bolnikih, ki imajo močno okvarjeno delovanje jeter ali ledvic, se priporoča nižji odmerek.
Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive', which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). 
Zdravilo Alunbrig se uporablja samostojno in le, če je nedrobnocelični pljučni rak ALK-pozitiven, kar pomeni, da imajo rakave celice določene spremembe gena, ki tvori beljakovino, imenovano anaplastična limfomska kinaza (ALK).
For the full list of side effects and restrictions with Alunbrig, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Alunbrig glejte navodilo za uporabo.
Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. 
Alunbrig je zdravilo, ki se uporablja za zdravljenje odraslih z vrsto pljučnega raka, imenovano nedrobnocelični pljučni rak (NSCLC), ki so bili predhodno zdravljeni z zdravilom krizotinib.
How is Alunbrig used? 
Kako se zdravilo Alunbrig uporablja?
positive NSCLC, an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion. 
Pri bolnikih z ALK-pozitivnim nedrobnoceličnim pljučnim rakom nastaja nenormalna oblika anaplastične limfomske kinaze, ki rakave celice spodbuja k nenadzorovani delitvi in rasti.
How does Alunbrig work? 
Kako zdravilo Alunbrig deluje?
Alunbrig contains the active substance brigatinib. 
Vsebuje zdravilno učinkovino brigatinib.
Alunbrig was effective in treating patients with ALK-positive NSCLC previously treated with crizotinib. 
Zdravilo Alunbrig je bilo učinkovito pri zdravljenju bolnikov z ALK-pozitivnim nedrobnoceličnim pljučnim rakom, ki so bili predhodno zdravljeni s krizotinibom.
19 August 2014 EMA/515780/2014 
19. avgust 2014 EMA/515780/2014
• If you have any questions about your treatment, you should contact your doctor or pharmacist. 
• če imate dodatna vprašanja o vašem zdravljenju, se posvetujte z zdravnikom ali farmacevtom.
1 For more information, see here. 
1 Več informacij je na voljo tukaj.
Tel. +44 (0)20 7418 8427 E-mail: press@ema.europa.eu 
Tel.: +44 (0)20 7418 8427 E-pošta: press@ema.europa.eu
Both medicines have been authorised in the EU through national procedures for over 40 years. 
Obe zdravili sta bili v EU odobreni po nacionalnih postopkih in sta na voljo že več kot 40 let.
The product information for both creams will be updated with the following recommendations: 
Informacije o zdravilu za obe kremi bodo posodobljene z naslednjimi priporočili:
The review has been carried out by the Committee for Medicinal Products for Human Use (CHMP) responsible for questions concerning medicines for human use. 
Pregled je opravil Odbor za zdravila za uporabo v humani medicini (CHMP), pristojen za vprašanja, povezana z zdravili za uporabo v humani medicini.
A limit to the duration of use and other measures put in place to manage potential risk of side effects 
Omejitev trajanja uporabe in drugi ukrepi, sprejeti za obvladovanje možnega tveganja za neželene učinke
The CHMP issued an opinion in December 2013. 
Odbor CHMP je mnenje izdal decembra 2013.
• Both creams should not be used for more than 4 weeks. 
• nobena od teh krem se ne sme uporabljati več kot štiri tedne.
Treatment with both creams should be limited to a maximum duration of 4 weeks. 
Zdravljenje z obema kremama je treba omejiti na največ štiri tedne.
Linoladiol N is marketed in Bulgaria, Czech Republic, Estonia, Germany, Hungary, Latvia, Lithuania and Slovakia, while Linoladiol HN is marketed in Estonia, Germany, Latvia and Lithuania. 
Krema Linoladiol N se trži v Bolgariji, Češki republiki, Estoniji, Nemčiji, na Madžarskem, v Latviji, Litvi in na Slovaškem, krema Linoladiol HN pa v Estoniji, Nemčiji, Latviji in Litvi.
The German medicines agency asked the CHMP to carry out a full assessment of the benefit-risk balance of these medicines and to issue an opinion on whether their marketing authorisations should be maintained, varied, suspended or withdrawn across the European Union. 
Nemška agencija za zdravila je odbor CHMP zaprosila, da celovito oceni razmerje med tveganji in koristmi teh zdravil ter izda mnenje o tem, ali naj se dovoljenja za promet z njima v EU ohranijo, spremenijo, začasno umaknejo ali ukinejo.
The review of the topical estradiol-containing medicines Linoladiol N and Linoladiol HN was triggered on 24 May 2012 by Germany, under Article 31 of Directive 2001/83/EC. 
Pregled zdravil za topično uporabo Linoladiol N in Linoladiol HN, ki vsebujeta estradiol, je 24. maja 2012 sprožila Nemčija v skladu s členom 31 Direktive 2001/83/ES.
The CHMP's recommendations were sent to the European Commission which endorsed them and issued a final, legally binding decision valid throughout the EU on 19 August 2014. 
Odbor CHMP je priporočila poslal Evropski komisiji, ta pa jih je potrdila in 19. avgusta 2014 izdala končni pravno zavezujoči sklep, ki velja za celotno EU.
The Linoladiol N cream (0.01 %w/w) contains 100 microgram of estradiol per gram, while Linoladiol HN (0.005 %w/w, 0.4 %w/w) contains 50 microgram of estradiol and 4 mg of the corticosteroid prednisolone per gram. 
Krema Linoladiol N (0,01 % m/m) vsebuje 100 mikrogramov estradiola na gram, medtem ko krema Linoladiol HN (0,005 % m/m, 0,4 % m/m) vsebuje 50 mikrogramov estradiola in 4 mg kortikosteroida prednizolona na gram.
In December 2013, the CHMP had concluded a review of the benefits and risks of both creams and made recommendations on their use.1 Following a request by the company for a re-examination of Linoladiol N, the recommendations for this cream have been updated, taking into account new measures to manage the potential risk of side effects. 
Odbor CHMP je decembra 2013 zaključil pregled koristi in tveganj, povezanih z obema kremama, in podal priporočila za njuno uporabo.1 Potem ko je farmacevtska družba zahtevala ponoven pregled zdravila Linoladiol N, so bila priporočila za to kremo posodobljena ob upoštevanju novih ukrepov za obvladovanje možnega tveganja za neželene učinke.
The CHMP reiterated the need to limit treatment with both creams to 4 weeks because of their relatively high estradiol content and the potential risks of side effects from estradiol being absorbed systemically (throughout the body). 
Odbor CHMP je ponovno izpostavil, da je treba zdravljenje z obema kremama omejiti na štiri tedne, ker vsebujeta sorazmerno veliko količino estradiola in ker obstajajo možna tveganja za neželene učinke zaradi sistemske absorpcije estradiola (po celem telesu).
Systemic absorption of estradiol may be associated with risks similar to those seen in systemic hormone replacement therapy (HRT), including blood clots, stroke and endometrial (womb) cancer. 
Sistemska absorpcija estradiola bi lahko bila povezana s podobnimi tveganji, kot jih opažajo pri sistemskem hormonskem nadomestnem zdravljenju (HNZ) in vključujejo krvne strdke, možgansko kap in raka endometrija (maternice).
In addition, for Linoladiol N, the cream with the higher amount of estradiol, the CHMP has required the company to limit the amount of cream available in the packs to prevent patients from using them for longer than recommended. 
Poleg tega je odbor CHMP za kremo Linoladiol N, ki vsebuje večjo količino estradiola, zahteval, da farmacevtska družba omeji količino kreme, ki je na voljo v pakiranju, da se prepreči, da bi bolnice kremo uporabljale dlje časa, kot je priporočeno.
The product information of Linoladiol N and Linoladiol HN have been updated to inform patients and healthcare professionals about these potential risks. 
Informacije o zdravilu za kremi Linoladiol N in Linoladiol HN so bile posodobljene tako, da bodo bolnice in zdravstveni delavci seznanjeni s temi možnimi tveganji.
If you have been using Linoladiol HN for this condition, contact your doctor to discuss alternative treatments. 
Če ste kremo Linoladiol HN uporabljali za to bolezen, se posvetujte z zdravnikom o drugih možnostih zdravljenja;
Linoladiol N and Linoladiol HN are a type of local ‘hormone replacement therapy': they contain a female hormone, estradiol, used to replace the estradiol hormone the body no longer makes after menopause. 
Kremi Linoladiol N in Linoladiol HN sta vrsta lokalnega „hormonskega nadomestnega zdravljenja“: vsebujeta ženski hormon estradiol, ki se uporablja za nadomeščanje hormona estradiola, ki ga telo po menopavzi ne proizvaja več.
• Linoladiol HN should no longer be prescribed for lichen sclerosus. 
• krema Linoladiol HN se ne sme več predpisovati za lichen sclerosus;
This is because the creams contain the hormone estradiol which can be absorbed into the bloodstream and may increase your risks of side effects such as blood clots and strokes if the creams are used for extended periods. 
Razlog za to je, da kremi vsebujeta hormon estradiol, ki se lahko absorbira v krvni obtok in lahko, če se kremi uporabljata daljše obdobje, poveča tveganje za neželene učinke, kot so krvni strdki in možganska kap;
On 25 April 2014, the EMA's Committee for Medicinal Products for Human Use (CHMP) updated recommendations on the use of two high-strength estradiol-containing creams, Linoladiol N and Linoladiol HN. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Evropski agenciji za zdravila je 25. aprila 2014 posodobil priporočila za uporabo krem velike jakosti Linoladiol N in Linoladiol HN, ki vsebujeta estradiol.
• Both Linoladiol N and Linoladiol HN should not be used beyond four weeks due to the risks associated with possible systemic exposure to estradiol. 
• kremi Linoladiol N in Linoladiol HN se zaradi tveganj, povezanih z možno sistemsko izpostavljenostjo estradiolu, ne smeta uporabljati več kot štiri tedne.
In addition, Linoladiol HN is no longer to be used to treat lichen sclerosus, a skin condition that commonly affects the genital area, because of a lack of evidence of benefit in this condition. 
Poleg tega se krema Linoladiol HN ne sme več uporabljati za zdravljenje lichen sclerosus, bolezni kože, ki pogosto prizadene spolovila, saj ni dovolj dokazov o koristih pri tej bolezni.
Linoladiol HN also contains low-dose prednisolone, which acts as an anti-inflammatory agent. 
Krema Linoladiol HN vsebuje tudi nizkoodmerni prednizolon, ki deluje protivnetno.
The EMA has concluded a review of Linoladiol N and Linoladiol HN estradiol-containing creams and has updated recommendations on their use. 
Evropska agencija za zdravila je zaključila pregled krem Linoladiol N in Linoladiol HN, ki vsebujeta estradiol, in posodobila priporočila za njuno uporabo.
• Linoladiol HN was previously being used to treat a condition called lichen sclerosus. 
• krema Linoladiol HN se je v preteklosti uporabljala za zdravljenje bolezni, imenovane lichen sclerosus.
The Linoladiol N cream is only to be used inside the vagina for treating postmenopausal women with vaginal atrophy due to a lack of the hormone estrogen, while the Linoladiol HN cream is for postmenopausal women with mild, inflammatory skin conditions around the genital area. 
Krema Linoladiol N je namenjena samo za uporabo v nožnici za zdravljenje žensk po menopavzi, ki imajo atrofijo nožnice zaradi pomanjkanja hormona estrogena, krema Linoladiol HN pa je namenjena ženskam po menopavzi, ki imajo blago vnetno bolezen kože okoli spolovil.
• Linoladiol N should be applied into the vagina while Linoladiol HN should be applied to the external genital area. 
• kremo Linoladiol N je treba nanesti v nožnico, kremo Linoladiol HN pa na zunanja spolovila;
• Linoladiol HN is indicated in the short-term treatment of acute, mild inflammatory skin diseases of the external genital area in postmenopausal women. 
• krema Linoladiol HN je indicirana za kratkotrajno zdravljenje akutnih blagih vnetnih bolezni kože zunanjih spolovil pri ženskah po menopavzi;
Following a request from the company, a reexamination of the opinion for Linoladiol N was carried out and concluded in April 2014. 
Na zahtevo farmacevtske družbe je bil aprila 2014 opravljen in zaključen ponoven pregled mnenja o zdravilu Linoladiol N. Končno mnenje odbora CHMP je bilo poslano Evropski komisiji, ki je 19. avgusta 2014 izdala končni sklep.
The European Medicines Agency has updated advice on how to use Linoladiol N and Linoladiol HN creams. 
Evropska agencija za zdravila je posodobila priporočila o tem, kako uporabljati kremi Linoladiol N in Linoladiol HN. Bolnice, ki uporabljajo ti kremi, morajo upoštevati naslednje:
• Linoladiol N is indicated for the treatment of vaginal atrophy due to estrogen deficiency in postmenopausal women. 
• krema Linoladiol N je indicirana za zdravljenje atrofije nožnice zaradi pomanjkanja estrogena pri ženskah po menopavzi;
• Linoladiol HN should only be used for treating postmenopausal women with mild, inflammatory skin conditions affecting the external genital area. 
• krema Linoladiol HN se lahko uporablja samo za zdravljenje žensk po menopavzi, ki imajo blago vnetno bolezen kože, ki prizadene zunanja spolovila;
• Linoladiol N is only to be used inside the vagina for treating postmenopausal women with vaginal atrophy due to a lack of estrogen. 
• krema Linoladiol N se lahko uporablja samo v nožnici za zdravljenje žensk po menopavzi, ki imajo atrofijo nožnice zaradi pomanjkanja estrogena;
A reduction of 6 points is considered a clinically meaningful improvement. 
Zmanjšanje za 6 točk velja za klinično pomembno izboljšanje.
You will also need: 
Potrebujete tudi:
Results of the subgroup analysis were consistent with overall study results for all subjects. 
Rezultati analize podskupine so bili skladni s splošnimi rezultati študije za vse preiskovance.
All antibody titres were low. 
Vsi titri protiteles so bili nizki.
There are also links to other websites about rare diseases and treatments. 
Tam najdete tudi povezave do drugih spletnih strani o redkih boleznih in zdravljenju.
Your doctor will discuss with you the risks and benefits of taking this medicine. 
Zdravnik se bo z vami pogovoril o tveganjih in koristih uporabe tega zdravila.
There is no antidote available. 
Antidota ni na voljo.
Interim analysis indicates that the effect was sustained up to one year of treatment. 
Vmesna analiza kaže, da se je učinek v enem letu zdravljenja ohranil.
Repeat these steps until large air bubbles are removed. 
Te korake ponavljajte, dokler ne odstranite velikih zračnih mehurčkov.
Important: 
Pomembno:
Results of primary and secondary efficacy measures-ITT population 
Rezultati primarnih in sekundarnih meril učinkovitosti - populacija ITT
Health related Quality of Life 
Kakovost življenja, povezana z zdravjem
E-mail: medinfoEMEA@shire.com 
E-pošta: medinfoEMEA@shire.com
Lower scores indicate lower impairment (or better health-related quality of life). 
Manjše vrednosti rezultata pomenijo manjšo okvaro (oziroma boljšo kakovost življenja, povezano z zdravjem).
If symptoms should occur, symptomatic treatment is recommended. 
Če se simptomi pojavijo, je priporočljivo simptomatsko zdravljenje.
Adjusted p-values for multiple testing. 
Prilagojene p-vrednosti za večkratno testiranje.
Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed child cannot be excluded during this short period. 
Znano je, da se humani IgG v prvih nekaj dneh po rojstvu izločajo v materino mleko, nato pa kmalu padejo na nizke koncentracije; posledično v tem kratkem obdobju tveganja za dojenega otroka ni mogoče izključiti.
• It is important to use different injection sites to keep skin healthy. 
• Pomembno je, da uporabljate različna mesta injiciranja, da ostaja koža zdrava.
There is no available information to identify potential signs and symptoms of overdose. 
Za opredelitev možnih znakov in simptomov prevelikega odmerjanja ni razpoložljivih informacij.
Important: Do not shake. 
Pomembno: Ne stresajte.
Adjusted p-values d 
Prilagojene p-vrednosti d
Important: Be sure to inject into a subcutaneous space which is not too shallow (skin layer) or too deep (muscle). 
Pomembno: Prepričajte se, da injicirate v podkožno mesto, ki ni preplitko (kožna plast) ali pregloboko (mišica).
Chemical and physical in-use stability has been demonstrated for 2 hours at 25°C and for 8 hours at 2°C to 8°C. 
Kemična in fizična stabilnost med uporabo je bila dokazana za 2 uri pri temperaturi 25 °C in za 8 ur pri temperaturi od 2 °C do 8 °C.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side affects you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
The anticipated time to reach steady state concentration was approximately 70 days. 
Pričakovani čas do doseganja koncentracij v stanju dinamičnega ravnovesja je bil približno 70 dni.
Each pack also contains the following items: 
Eno pakiranje vsebuje tudi naslednje pripomočke:
There were no differences in international normalised ratio (INR) between treatment groups. 
Med skupinami zdravljenja ni bilo razlike v internacionalnem normaliziranem razmerju (INR).
This helps to reduce the amount of bradykinin in your bloodstream and prevents symptoms of HAE. 
To pomaga zmanjšati količino bradikinina v krvnem obtoku in prepreči simptome HAE.
This is because it has not been studied in this age group. 
Zdravila namreč v tej starostni skupini niso preučili.
Vials may be stored below 25°C for a single period of 14 days, but not beyond the expiry date. 
Viale lahko shranite pri temperaturi, nižji od 25 °C, za enkratno 14-dnevno obdobje, vendar ne dlje od datuma izteka roka uporabnosti zdravila.
The mean (SD) volume of distribution of lanadelumab in patients with HAE is 14.5 litres (4.53). 
Povprečni (SD) volumen porazdelitve lanadelumaba pri bolnikih s HAE je 14,5 litra (4,53).
Do not touch the needle tip or allow it to touch any other surface. 
Konice igle se ne dotikajte in ne pustite, da se dotakne druge površine.
% reduction relative to placebo corresponds to 100% * (1-rate ratio). 
% zmanjšanje glede na placebo ustreza 100 % * (1-razmerje pojavnosti).
The injection of TAKHZYRO can be summarised in 5 steps: 
Injiciranje zdravila TAKHZYRO lahko povzamemo v 5 korakih:
f) Check the solution in the vial for particles or a change in the colour (normally it is colourless to slightly yellow). 
f) Preverite, ali raztopina v viali vsebuje delce oz. je spremenila barvo (običajno je brezbarvna do rahlo rumena).
If you inject TAKHZYRO yourself or if your caregiver injects it, you or your caregiver must carefully read and follow the instructions in section 7, “Instructions for use”. 
Če si zdravilo TAKHZYRO injicirate sami ali vam ga injicira negovalec, morate vi ali vaš negovalec natančno prebrati in upoštevati navodila v poglavju 7, »Navodila za uporabo«.
[mild, N=98] and 30 to 59 ml/min/1.73m 
[blaga, N = 98] in od 30 do 59 ml/min/1,73 m
Note: CI=confidence interval; LS=least squares. 
Opomba: IZ = interval zaupanja; LS = metoda najmanjših kvadratov (least squares).
The frequency of adverse reactions listed in Table 1 is defined using the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Pogostnost spodaj naštetih neželenih učinkov, navedenih v preglednici 1, je opredeljena po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
It is important that you keep injecting TAKHZYRO as instructed by your doctor even if you feel better. 
Pomembno je, da si zdravilo TAKHZYRO redno injicirate, kot vam je naročil zdravnik, četudi se počutite bolje.
• Inject the medicine in a different place each time. 
Zdravilo si vsakič injicirajte v drugo mesto.